Comparative Pharmacology
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBINOXAMINE MALEATE versus KETOTIFEN FUMARATE.
CARBINOXAMINE MALEATE vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine maleate is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Adults: 4-8 mg orally every 6-8 hours as needed. Maximum: 24 mg/day.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment, requiring dose adjustment in significant liver disease.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Primarily renal excretion of metabolites and unchanged drug; ~60-70% of a dose is excreted in urine within 48 hours, with less than 5% as unchanged drug. Biliary/fecal elimination accounts for a minor fraction (<10%).
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer